Related Experiment Videos

[Ischemic heart disease in elderly patients of behavioral type A (psychosocial and clinic functional changes,

V N Fedorets

    Advances in Gerontology = Uspekhi Gerontologii
    |August 4, 2011
    PubMed

    Insights

    This study found that Anaprilin, Metoprolol, and Phenazepam effectively improved psychological and clinical outcomes in elderly patients with coronary heart disease (CHD) and Type A behavior. Treatment reduced symptoms and enhanced quality of life.

    Area of Science:

    • Cardiology
    • Psychiatry
    • Endocrinology

    Context:

    • Elderly patients with coronary heart disease (CHD) often exhibit Type A behavioral patterns.
    • Psychosocial factors significantly influence CHD prognosis and management in older adults.

    Purpose:

    • To evaluate the clinical efficacy of Anaprilin, Metoprolol, and Phenazepam, alongside non-medical interventions, in elderly CHD patients with Type A behavior.
    • To assess the impact of these treatments on psychoendocrine parameters and personality profiles.

    Summary:

    • Combined therapy including Anaprilin, Metoprolol, and Phenazepam improved clinical symptoms like angina and arrhythmia in elderly CHD patients.
    • Treatment led to significant reductions in neurotic triad scores, psychoasthenia, and reactive anxiety.
    • Psychoendocrine markers, including aldosterone, cortisol, triiodothyronine, and thyroxine, decreased post-treatment.

    Impact:

    • Supplementation of Anapriline, Metoprolol, and Phenazepam positively influenced the clinical course of CHD in Type A elderly patients.
    • Therapy contributed to leveling personality profiles and reducing Type A behavioral characteristics.
    • The findings suggest optimized treatment strategies for managing CHD in this specific patient population.

    Related Concept Videos

    Pharmacodynamics in Geriatric Patients: Effects of Age01:27

    Pharmacodynamics in Geriatric Patients: Effects of Age

    Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
    Drug Dosing: Geriatric Patients01:15

    Drug Dosing: Geriatric Patients

    Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
    Atherosclerosis IV: Nursing Management01:23

    Atherosclerosis IV: Nursing Management

    Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...